A Study to Evaluate Whether Participants With Melanoma Prefer Subcutaneous vs Intravenous Administration of Nivolumab and Nivolumab + Relatlimab Fixed-dose Combinations

Number of Participants With Adverse Events and Deaths

An adverse event is any untoward medical occurrence that begins or worsens after the first dose of study treatment, including any unfavorable sign, symptom, disease, or abnormal lab finding, whether or not related to the product, and may include worsening of pre-existing conditions. A Serious Adverse Event (SAE) is any untoward medical occurrence that results in death, is life-threatening, requires or prolongs hospitalization, causes persistent or significant disability/incapacity, leads to a congenital anomaly/birth defect, or is considered an important medical event requiring intervention to prevent these outcomes.

Time frame: First dose (Day 1) and 30 days after last dose of study therapy (up to approximately 16 months)

Number of Participants With Laboratory Abnormalities and Immune Mediate Adverse Event

Time frame: From first dose (Day 1) and up to study completion (up to approximately 45 months)